Wound Infection

3
Pipeline Programs
3
Companies
1
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
3
Early DiscoveryClinical DevelopmentMarket

On Market (2)

Approved therapies currently available

U
CUBICINApproved
daptomycin
Unknown Company
intravenous2003
U
CUBICIN RFApproved
daptomycin
Unknown Company
intravenous2003

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
1 program
1
DaptomycinPhase 41 trial
Active Trials
NCT01080963Completed650Est. Mar 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
NovartisDaptomycin

Clinical Trials (1)

Total enrollment: 650 patients across 1 trials

Daptomycin as Antibiotic Prophylaxis of Sternal Wound Infections

Start: Nov 2008Est. completion: Mar 2012650 patients
Phase 4Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space